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ABSTRACT
Pre- vs. post-vaccination changes in correlations between IgG concentrations (ELISA titres) and
opsonophagocytic activity (OPA) against Streptococcus pneumoniae serotypes 6B, 14 and 23F induced by
the 23-valent polysaccharide vaccine were studied in paired serum samples received from elderly
individuals, haemodialysed patients and kidney transplant recipients by the Spanish Pneumococcal
Reference Laboratory. The pre- and post-vaccination parameters considered were: ELISA and OPA titres
and the percentage of subjects with post-vaccination OPA values above the cut-off levels; the
correlations between OPA and ELISA (Spearman correlation coefﬁcient, r); and the amount of IgG
needed to obtain OPA (b coefﬁcient). Non-signiﬁcant pre-vaccination correlations between OPA and
ELISA were found. Vaccination increased the correlation coefﬁcient between OPA and ELISA to a
statistically signiﬁcant level for serotypes 6B, 14 and 23F in samples from haemodialysed patients, for
serotypes 14 and 23F in samples from elderly individuals, and for none of the serotypes in samples from
transplant recipients. In all cases, except for serotype 23 in transplant recipients, vaccination increased
the b coefﬁcient, indicating that lower amounts of IgG were needed to obtain high OPA titres. A globally
lower response was obtained for serotype 23 and ⁄ or transplant recipients.
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INTRODUCTION
Polysaccharide type-speciﬁc antibodies mediating
opsonin-dependent phagocytosis [1,2] are consid-
ered to be the primary mechanism of host
protection against Streptococcus pneumoniae.
Therefore, although ELISA has been used widely
to establish protection correlates in the sera of
vaccinees [3], the in-vitro determination of opso-
nophagocytic activity (OPA) of antibodies to
pneumococcal capsule polysaccharides is consid-
ered to provide a measure of their functional
activity, and may represent a better surrogate
marker for in-vivo protection [4]. In this respect,
clinical data and studies in mice indicate that
OPA may provide a good basis for measuring
protection [5,6]. Nevertheless, OPA assays have
not been completely standardised or validated
[2,4,5,7]. As there is no ideal in-vitro serological
correlate of protection for establishing effective-
ness in preventing pneumococcal disease, the
3rd International Symposium on Pneumococci
and Pneumococcal Diseases (Anchorage, Alaska,
2002) recommended that OPA measurements
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should supplement ELISAs [8] in establishing
correlates of protection when evaluating sera of
vaccinees [2,9].
Pneumococcal polysaccharides included in the
pneumococcal polysaccharide vaccine have the
properties of T-cell-independent type 2 antigens,
i.e., poor induction of memory B-cells and a
restricted IgG response [10,11], with total IgG
concentrations of speciﬁc antibodies being the
most important factor contributing to pneumo-
coccal opsonophagocytosis [4]. Pneumococcal
polysaccharide vaccination has become the stand-
ard of care for several population groups, inclu-
ding the elderly and patients with chronic renal
failure [12], for prevention of pneumococcal
disease caused by the most prevalent serotypes.
The most common serotypes isolated in Spain
are serotypes 19, 6, 23, 14, 3 and 9, which together
comprise 61% of pneumococcal isolates [13].
Among penicillin-resistant pneumococci, 83% of
isolates belong to serotypes 23, 14, 6, 19 and 9,
which are the so-called penicillin resistance-asso-
ciated serotypes [14]. Of the penicillin resistance-
associated serotypes, serotypes 6, 14 and 23 also
show very high rates (>40%) of macrolide resist-
ance in Spain [13,15].
Since the quantitative and qualitative character-
istics of antibodies (e.g., antibody concentration
and avidity) contribute to OPA and the estimation
of immunity, correlations between the measured
concentrations of IgG and OPAs of antibodies are
required [16]. The present study explored the effect
of pneumococcal polysaccharide vaccination for
serotypes 6, 14 and 23 on such correlations by
comparing the pre- and post-vaccination immune
status in paired serum samples received at the
Spanish Pneumococcal Reference Laboratory from
elderly individuals, haemodialysed patients and
recipients of renal transplants.
MATERIALS AND METHODS
Subjects, vaccine and vaccination
In total, 74 pairs of sera (pre-vaccination and 1 month post-
vaccination) from adults were studied at the Spanish Pneu-
mococcal Reference Laboratory (Instituto de Salud Carlos III,
Majadahonda, Madrid, Spain). Twenty-one pairs of sera were
from elderly individuals (aged ‡65 years), 42 were from
patients undergoing haemodialysis, and 11 were from kidney
transplant recipients. The mean age (±SD) and proportion of
males in these three groups were 75.3 ± 7.4 years and 42.9%,
62.2 ± 16.3 years and 59.5%, and 50.1 ± 12.3 years and 36.4%,
respectively. All subjects had received a single injection of the
23-valent S. pneumoniae polysaccharide vaccine (Aventis Pas-
teur S.A., Marcy l’Etoile, France) immediately after the ﬁrst
blood sample (pre-vaccination serum sample). The post-vac-
cination sample was collected at least 1 month after vaccin-
ation. In the case of kidney transplant recipients, vaccination
was performed at least 6 months after transplantation.
Speciﬁc anti-capsular antibody determination
ELISAs were performed as described previously [17,18], with
minor modiﬁcations to determine the concentration of speciﬁc
anti-capsular IgG to pneumococcal serotypes 6B, 14 and 23F. In
brief, serum reference standards, quality control specimens
and test specimens were adsorbed with a 1:50 dilution of a
10 mg ⁄L preparation of cell-wall polysaccharide (Statens
Seruminstitut, Copenhagen, Denmark). ELISA microtitre
plates (Nunc Maxisorp; PGC Scientiﬁcs Corp., Gaithersburg,
MD, USA) were coated with 0.5 lg of puriﬁed polysaccharide
antigen (ATCC, Manassas, VA, USA). Every plate included
paired pre- and post-vaccination samples, an in-house refer-
ence standard serum with calculated concentrations of IgG to a
speciﬁc polysaccharide (based on cross-standardisation with
the 89-SF serum reference standard, kindly provided by C. E.
Frasch, Centers for Biologics, Rockville, MD, USA), four
quality controls and a negative serum specimen that did not
contain IgG to the individual polysaccharide studied. Data are
presented as IgG mg ⁄L.
Pneumococcal strains
The pneumococcal serotypes selected for the OPA were 6B, 14
and 23F. Pneumococcal strains were obtained from the Spanish
Pneumococcal Reference Laboratory and were serotyped as
described previously [19].
Opsonophagocytic activity titres
Flow-cytometric determination of OPA for each of the three
serotypes was performed essentially as described previously
[20], but with minor modiﬁcations [9]. Three strains of
serotypes 6B, 14 and 23F were grown three times consecutively
to log-phase in Todd–Hewitt medium supplemented with
decomplemented human pooled serum 1% v ⁄v to ensure a
high level of encapsulation, as a critical step for measuring
speciﬁc anti-capsular antibodies [21]. Subsequently, the strains
were heat-inactivated and labelled with ﬂuorescein isothiocy-
anate. Pooled human serum was depleted of IgG by protein G
afﬁnity chromatography and used as a complement source. In
optimising experiments, the addition of complement did not
signiﬁcantly change OPA titres relative to corresponding
strains that had not been heat-inactivated. This ensured a
high degree of encapsulation of the strains used in the assay.
Human polymorphonuclear leukocytes (PMNs) were iso-
lated from the blood of healthy, Fcc receptor-typed volunteers
[22] by Ficoll–Histopaque gradient centrifugation. Sera from
vaccinees were heated (30 min at 56C) to inactivate the
complement before it was assayed. Samples of 2.5 · 106
pneumococci, and three serial ﬁve-fold dilutions, starting with
a serum sample diluted 1:10, were added to each of the 96
wells of a microtitre plate (ratio of PMNs to bacteria = 1:20).
After opsonisation for 30 min at 37C on a microtitre plate
shaker, 1.25 · 105 freshly isolated PMNs were added to each
well and phagocytosis was performed for 30 min at 37C with
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vigorous shaking. After three washing steps with ice-cold
bovine serum albumin–Hank’s balanced salt solution, cells
were transferred to ﬂuorescence-activated cell-sorter tubes,
ﬁxed immediately with paraformaldehyde 2% v ⁄v in phos-
phate-buffered saline, and analysed in a ﬂow-cytometer
(FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA).
The percentage of ﬂuorescein isothiocyanate-positive PMNs
was used as a measure of the phagocytic activity of the serum.
Results are expressed as log10 of the phagocytosis titre, which
is the reciprocal of the serum dilution yielding 25% ﬂuorescein
isothiocyanate-positive PMNs. A positive control serum was
included on each plate to control the reproducibility of the
assay.
OPA cut-off levels, taken empirically from previous studies
performed with serum samples from different populations,
were ‡4 for serotype 6, ‡25 for serotype 14, and ‡6 for serotype
23 [9].
Study evaluation parameters and endpoints
Evaluation parameters and endpoints of the study were: (a)
inter-group (elderly, haemodialysis and renal transplant)
comparison of pre-vaccination IgG (mg ⁄L) and OPA titres;
(b) intra-group comparison of pre- vs. post-vaccination IgG;
(c) intra-group comparison of pre- vs. post-vaccination OPA
titres; (d) intra-group comparison of the pre- vs. post-vaccin-
ation percentage of subjects with OPA titres above the OPA cut-
off levels; (e) pre- and post-vaccination correlation (Spearman
coefﬁcient, r) between IgG and OPA titres per group and
serotype pair; and (f) b coefﬁcient of the linear equation (slope)
of these pre- and post-vaccination correlations, as quantiﬁcation
of the amount of IgG needed to obtain OPA (the higher the
b-value, the lower the amount of IgGneeded to obtain highOPA
titres).
Statistical analysis
Data were described using median and inter-quartile range
because of the non-Gaussian data distribution. Pre-vaccination
values of ELISA and OPA were compared by the Mann–
Whitney test with Bonferroni correction, establishing statistical
signiﬁcance at 0.017 in order to adjust multiple comparisons.
Comparison of pre- vs. post-vaccination data was performed
using the non-parametric Wilcoxon test. Comparisons between
the pre- and post-vaccination percentages of subjects with
OPA titres above the OPA cut-off levels were performed by the
McNemar test. Correlations between OPA and ELISA were
calculated using the non-parametric Spearman correlation test.
A line of regression between variables was estimated by linear
regression analysis, using the b coefﬁcient (y = a + bx) as line
slope. All the analyses were performed using SPSS v.9.0 (SPSS
Inc., Chicago, IL, USA), with p <0.05 considered as statistically
signiﬁcant for all tests, except when indicated otherwise. All
ELISA and OPA values were included in the correlation
analysis, but points corresponding to ELISA and ⁄or OPA
values >100 were excluded from the graphical representation
for clarity.
RESULTS
Table 1 shows pre- and post-vaccination ELISA
IgG concentrations, OPA titres and the number
and percentage of subjects with OPA titres above
the OPA cut-off levels in the three study groups.
Signiﬁcantly (p <0.017) higher pre-vaccination
IgG values and OPA titres were obtained for
serotypes 6 and 14 in haemodialysed patients
(median values of 4.9 and 9.9 for IgG, and 9.0 and
12.0 for OPA, respectively) vs. elderly individuals
(median values of 1.7 and 4.9 for IgG, and 2.0 and
5.0 for OPA, respectively). For serotype 23, signi-
ﬁcantly lower OPA titres were obtained for hae-
modialysed patients (2.0 vs. 7.0), while for renal
transplant recipients, signiﬁcantly higher OPA
Table 1. Pre- and post-vaccination ELISA IgG concentrations and opsonophagocytic activity (OPA) titres (median and
inter-quartile ranges), and the number and percentage of subjects with OPA titres above the OPA cut-off levels in the three
study groups
Patients
Serotype 6 Serotype 14 Serotype 23
ELISA OPA
OPA ‡4
n (%) ELISA OPA
OPA ‡25
n (%) ELISA OPA
OPA ‡6
n (%)
Elderly (n = 21)
Pre-vaccination 1.7 2.0 6 4.9 5.0 0 2.9 7.0 14
(1.2–3.0) (1.0–4.0) (28.6) (1.7–7.7) (1.5–10.0) (0) (0.9–4.4) (3.0–12.5) (66.7)
Post-vaccination 3.0 20.0 19 10.1 28.0 11 5.5 6.0 11
(1.5–10.0) (11.0–36.5) (90.5) (3.7–48.0) (6.0–33.0) (52.4) (2.0–8.9) (3.0–25.0) (52.4)
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.322 0.345
Haemodialysis (n = 42)
Pre-vaccination 4.9a 9.0a 32 9.9a 12.0a 17 4.1 2.0a 13
(2.1–7.9) (3.8–20.3) (76.2) (4.7–21.0) (5.0–32.0) (40.5) (1.8–8.4) (1.0–6.0) (31.0)
Post-vaccination 6.8 23.0 39 20.5 19.0 18 8.4 4.5 19
(3.0–16.3) (11.0–50.0) (92.9) (9.4–54.2) (11.8–52.8) (42.9) (3.2–13.9) (2.0–11.8) (45.2)
p 0.001 <0.001 0.07 <0.001 0.012 1 0.006 0.006 0.26
Renal transplant (n = 11)
Pre-vaccination 1.7 6.0a 8 4.6 5.0 0 2.2 2.0 1
(1.1–3.2) (3.0–34.0) (72.7) (2.4–12.5) (3.0–7.0) (0) (1.4–4.1) (1.0–3.0) (9.1)
Post-vaccination 2.7 15.0 10 12.6 26.0 6 4.4 4.0 1
(1.9–5.6) (8.0–50.0) (90.9) (5.4–24.2) (14.0–33.0) (54.5) (2.4–6.3) (3.0–5.0) (9.1)
p 0.061 0.03 0.58 0.021 0.003 <0.001 0.032 0.108 1
ap <0.017 vs. elderly.
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titres vs. those of elderly subjects were obtained
only for serotype 6.
As shown in Table 1, a signiﬁcant (p <0.05)
increase in post-vaccination IgG values, together
with a signiﬁcant increase in OPA titres, was
obtained for serotypes 6 and 14 in elderly and
haemodialysed patients, for serotype 23 in hae-
modialysed patients, and for serotype 14 in the
case of transplant recipients. A signiﬁcant in-
crease in IgG values without an increase in OPA
titres was obtained with serotype 23 vaccination
in elderly patients and transplant recipients,
while no increase in IgG levels combined with a
signiﬁcant increase in OPA titres was obtained
with serotype 6 vaccination in renal transplant
recipients. The lowest median post-vaccination
OPA titres (£6.0) were obtained for serotype 23,
regardless of the group of patients, while median
post-vaccination OPA titres for serotype 14 were
‡19.0, and those for serotype 6 were ‡15.0. The
number of subjects with OPA titres above the
OPA cut-off titres increased signiﬁcantly for
serotypes 6 and 14 only in the elderly, and in
none of the three populations for serotype 23,
despite the signiﬁcant post-vaccination increase in
OPA titres in most cases.
Figs 1–3 show the distribution of IgG concen-
trations and associated OPA titres (from the same
sample) before and after vaccination in the three
study populations. For the ﬁgs, but not for the
analysis, pairs of IgG and OPA measurements
that were outside the scale (values >100 for IgG
and ⁄ or OPA) were excluded: two post-vaccin-
ation points (caused by high ELISA values) in the
elderly group for serotype 14; four post-vaccin-
ation points (caused by high OPA titres) for
serotype 6, two pre-vaccination points (caused by
high ELISA values), and nine post-vaccination
points (caused by high OPA titres) for serotype 14
in haemodialysed patients; and one pre- and one
post-vaccination point (caused by high OPA
titres) for serotype 6 in renal transplant recipients.
Table 2 shows the Spearman correlation coefﬁ-
cient and the slope (b coefﬁcient) of the linear
equation for the pre- and post-vaccination corre-
lations between IgG and OPA. Vaccination
increased these correlations (increased r values),
and the statistical signiﬁcance for all serotypes in
haemodialysed patients, for serotypes 14 and 23
in the elderly group, but for none of the three
serotypes studied in renal transplant recipients. In
the latter case, pre-vaccination correlations for
serotypes 6 and 14 were already high (0.797 and
0.514, respectively). Arbitrarily considering corre-
lations between IgG and OPA with an r value >0.5
as high, post-vaccination high correlations were
found in all three patient groups for serotype 14,
in none for serotype 23, and in haemodialysed
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Fig. 1. Distribution of antibody concentrations (ELISA)
and opsonophagocytic activity (OPA) titres pre-vaccin-
ation (open circles; dotted line) and post-vaccination (black
squares; continous line) for serotypes 6, 14 and 23 in
elderly patients.
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patients and renal transplant recipients for sero-
type 6.
When studying the quantiﬁcation of the
amount of IgG needed to obtain OPA, the
b coefﬁcient of the linear equation (slope) of these
pre- and post-vaccination correlations (Table 2,
Figs 1–3) was used; the higher the b value, the
lower the amount of IgG needed to obtain
high OPA titres. In all cases, except for serotype
23 in renal transplant recipients, vaccination
increased the b coefﬁcient. High b coefﬁcients
were obtained post-vaccination for serotypes 6
Serotype 6
0
10
20
30
40
50
60
70
80
90
100
ELISA
O
PA
0 20 40 60 80 100
O
PA
Serotype 14
0
10
20
30
40
50
60
70
80
90
100
ELISA
0 20 40 60 80 100
O
PA
Serotype 23
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100
ELISA
Fig. 2. Distribution of antibody concentrations (ELISA)
and opsonophagocytic activity (OPA) titres pre-vaccin-
ation (open circles; dotted line) and post-vaccination (black
squares; continous line) for serotypes 6, 14 and 23 in
haemodialysed patients.
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Fig. 3. Distribution of antibody concentrations (ELISA)
and opsonophagocytic activity (OPA) titres pre-vaccin-
ation (open circles; dotted line) and post-vaccination (black
squares; continous line) for serotypes 6, 14 and 23 in renal
transplant recipients.
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and 14 in haemodialysed patients, and for sero-
type 6 in renal transplant recipients, although in
the latter case the pre-vaccination value was
already high.
DISCUSSION
Polysaccharide vaccine-induced protection
against S. pneumoniae has been determined
through vaccine efﬁcacy trials [12,23] that have
shown different degrees of protection, depending
on the endpoint measured and the population
studied. Efforts have been made to identify and
standardise laboratory correlates of protection
that can aid vaccine efﬁcacy trials in the estima-
tion of vaccine-induced protection. Analysis of
sera from adults has shown that detection of
antibodies to serotype 14 by ELISA is serotype-
speciﬁc, whereas detection of antibodies to other
serotypes is hampered by cross-reactivity [24,25].
These cross-reactive antibodies are more preval-
ent in pre-vaccination sera than in post-vaccin-
ation sera [26], suggesting that the majority of
antibodies induced by vaccination with the poly-
saccharide vaccine are polysaccharide type-speci-
ﬁc or group-speciﬁc [27]. The quantity and quality
of antibodies required for protection against
pneumococcal infections remain unknown, and
may be different for mucosal and invasive infec-
tions, and may differ among populations and
epidemiological settings. Efforts have focused on
the identiﬁcation of alternative assays that can
measure the function of the anti-capsular anti-
bodies and could serve as correlates of protection
against disease. Several different OPA assays
have been developed to measure the functionality
of anti-pneumococcal antibodies [7,28]. Clinical
data and studies in mice indicate that OPA may
provide a good basis for estimating the degree of
protection [5,6].
In some adult sera, mostly from unvaccinated
individuals, there is no direct correlation between
IgG measured by ELISA and OPA titres [2,4,7,16],
suggesting the presence of pre-vaccination,
non-speciﬁc, polyreactive and low-functionality
antibodies [4]. Absorption of sera with 22F poly-
saccharide to remove polyreactive non-speciﬁc
antibodies did not improve the poor correlations
between IgG concentrations and OPA titres found
in pre-vaccination sera [29]. In pre-study experi-
ments, absorption failed to remove non-functional
antibodies, since a similar reduction in pre-vac-
cination and post-vaccination IgG concentrations
was observed in paired samples (with and with-
out absorption) with a signiﬁcant OPA rate (data
not shown). Considering these data, and the fact
that assignments of concentrations from standard
reference serum (89S-F) are calculated without
22F adsorption, the 22F adsorption step was not
included in the ELISA determinations.
In agreementwith previous data concerning low
pre-vaccination OPA and ELISA correlations, the
present study found low, non-signiﬁcant, correla-
tions in the pre-vaccination status. These generally
increased (becoming statistically signiﬁcant) to
give r values >0.5 after vaccination against sero-
types 6 and 14, but not against serotype 23. For
serotype 23, despite the increase in statistical
signiﬁcance, correlations showed r <0.5, and
median post-vaccinationOPA titres remained very
low in the three populations tested. Post-vaccina-
tion OPA titres were much higher for serotypes 6
and 14 in the three populations, despite the fact
that all sera included in this study had an IgG
concentration >0.5 mg ⁄L, which is higher than the
putative protective level of 0.2 mg ⁄L [30].
In addition to post-vaccination correlations of
OPA and ELISA for serotypes 6 and 14, vaccin-
ation increased the b coefﬁcient (from <1 to >4) in
haemodialysed patients (Fig. 2), suggesting a
Table 2. Spearman coefﬁcient (r) (and its type I error, P) and b coefﬁcient of the linear equation of pre- and post-
vaccination correlations between ELISA antibody concentrations and opsonophagocytic activity in the three study groups
Patients
Serotype 6 Serotype 14 Serotype 23
r P b r P b r P b
Elderly (n = 21)
Pre-vaccination 0.318 0.161 )0.246 0.084 0.717 )0.093 0.041 0.858 0.001
Post-vaccination 0.264 0.247 0.546 0.641 0.002 0.395 0.434 0.049 0.684
Haemodialysis (n = 42)
Pre-vaccination 0.334 0.031 0.891 0.423 0.005 0.235 )0.068 0.670 )0.011
Post-vaccination 0.669 0.004 5.786 0.720 0.001 4.004 0.414 0.006 0.189
Renal transplant (n = 11)
Pre-vaccination 0.797 0.003 16.124 0.514 0.106 0.394 0.392 0.223 )0.253
Post-vaccination 0.674 0.023 19.584 0.539 0.087 0.585 0.334 0.315 )0.092
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post-vaccination need for lower IgG concentra-
tions to obtain high OPA titres. Again, the lowest
pre- and post-vaccination b coefﬁcient was
obtained for serotype 23, suggesting not only a
need for more IgG to obtain a signiﬁcant
OPA titre (antibody low afﬁnity), but also,
as observed previously, a low post-vaccination
correlation between both assays (antibody low
functionality).
With respect to pneumococcal infection pro-
phylaxis, a signiﬁcant increase in post-vaccination
OPA titres was obtained for serotypes 6 and 14 in
all three populations, while for serotype 23, the
signiﬁcant increase in IgG concentrations after
vaccination did not imply increases in OPA titres
in the elderly or transplant recipient patients.
Again, there was no increase in subjects exceeding
the OPA threshold after vaccination against ser-
otype 23.
Considering the populations studied, and tak-
ing into account pre-vaccination status, post-
vaccination correlations between OPA and ELISA
(r coefﬁcient), post-vaccination quantiﬁcation of
the amount of IgG needed to obtain OPA (b
coefﬁcient), post-vaccination OPA titres, and the
percentage of subjects with post-vaccination OPA
values above the cut-off levels, it seems that a
response to vaccination against serotypes 6 and 14
is much more valuable than the response against
serotype 23 in these three populations. In general,
a lower response was obtained in renal transplant
recipients, probably because of the previous use
of immunosuppressive drugs, which may impair
the patient’s response to vaccination [11]; this is
especially the case for serotype 23, which is one of
the less immunogenic serotypes [9].
The absence of a non-vaccinated control group
in this series prevents conclusions concerning the
vaccine causality of post-vaccination correlations.
Nevertheless, this study suggests a post-vaccin-
ation increase in IgG concentrations and antibody
functionality correlations, as well as a dependence
on the pre-vaccination immune status, the sero-
type studied and the target adult patient popula-
tion and its morbidity. It also highlights the
difﬁculty in interpreting serological data because
of the need to take into account not only serotype-
speciﬁc IgG concentrations, but also other param-
eters, e.g., the post-vaccination change in the
slope of the ELISA ⁄OPA correlations, in evaluat-
ing vaccination response with respect to high
OPA in different populations.
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